跳至主要内容
临床试验/NCT05662345
NCT05662345进行中(未招募)不适用

ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer

Menarini Silicon Biosystems, INC4 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2022年12月12日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
65
试验地点
4
主要终点
To prospectively evaluate the impact of CellSearch CTCs on treatment decisions and response assessment in MBC patients

研究概览

简要总结

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease
  • ER+/HER2- patients prior to starting 2nd line therapy or beyond OR ER/Progesterone Receptor (PR)/HER2-negative (Triple Negative) patients prior to starting any line of therapy
  • Measurable and/or non-measurable disease is allowed
  • Male or female breast cancer is allowed
  • Age > 18 years
  • Willingness to provide mandatory blood specimens
  • Willing to return to enrolling institution for follow up imaging at least once

排除标准

  • Life expectancy of ≤ 6 months
  • Inability to provide blood samples based on the judgment of the treating provider

结局指标

主要结局

To prospectively evaluate the impact of CellSearch CTCs on treatment decisions and response assessment in MBC patients

时间窗: 3 to 4 months

Assessing proportion of providers that find CellSearch CTCs helpful in determining response to therapy in each unique patient (Questionnaire #2).

次要结局

  • Assess barriers and receptiveness of providers in using CTCs in clinical practice(18 months)
  • Evaluate if CTC results correlate with response assessment and disease progression defined by standard of care imaging(18 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验